News
RMD
183.42
-0.20%
-0.36
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices. California-based company reported adjusted profit of $2.13 per share for the quarter ended March 31. Sales rose 7% to $1.2 billion. Shares of ResMed rose 9% in extended trading.
Reuters · 5h ago
Resmed Inc Q3 Profit Increases, beats estimates
NASDAQ · 6h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. Fresh2 Group stock rose 10.61% and ResMed stock rose 6.85% in the same session. The company's Q3 earnings came out today.
Benzinga · 7h ago
*ResMed 3Q R&D Expenses $226.7M >RMD
Dow Jones · 7h ago
Press Release: ResMed Inc. Announces Results for -3-
For the three and nine months ended March 31, 2017, we generated $ 300,492 in cash and cash equivalents. We generated $ 728,715 in net income and $ 667,892 in cash for the three months ending March 31. We expect to generate $1.2 billion in cash in the second quarter of 2018 and $2.1 billion in the third quarter. The Company's net income for the first three months of the year was $300,492.
Dow Jones · 7h ago
Press Release: ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024. Year-over-year revenue grows 7%, operating profit up 25%, and operating cash flows of $402 million. A webcast of ResMed's conference call will be available at 4:30 p.m. ET. Third Quarter 2024 revenue increased 7% to $1.2 billion.
Dow Jones · 7h ago
Noteworthy Thursday Option Activity: RMD, MDXG, XOM
NASDAQ · 8h ago
ResMed Q3 2024 Earnings Preview
Seeking Alpha · 1d ago
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
NASDAQ · 1d ago
Weekly Report: what happened at RMD last week (0415-0419)?
Weekly Report · 3d ago
ResMed Keeps Bull Amid Weight-Loss Drug Trials -- Market Talk
Jarden's analysts say Eli Lilly's weight-loss drug trial results were largely as anticipated. ResMed's CPAP machines remain the gold-standard for sleep apnea treatment, analysts say. Jarden keeps an overweight rating on ResMed and its Australia-listed securities.
Dow Jones · 04/19 01:23
ResMed's 3Q Profit to Beat Market Expectations -- Market Talk
ResMed's 3Q profit is likely to beat market expectations, Macquarie analysts say. They anticipate a March-quarter net profit of US$292 million on revenue of US $1.19 billion. Shares are up 1.8% at A$28.13.
Dow Jones · 04/19 00:26
*ResMed Target Price Raised 2.5% to A$34.30/Share by Macquarie>RMD.AU
Dow Jones · 04/18 23:01
RMD June 21st Options Begin Trading
NASDAQ · 04/18 14:54
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
ResMed Inc. (NYSE:RMD) has a 28.7x price-to-earnings ratio. The company has a strong earnings growth rate compared to most other companies in its industry. Its P/E ratio is higher than the average for the U.S. Stock market. ResMed is expected to grow its earnings by 16% over the next three years.
Simply Wall St · 04/18 10:51
BUZZ-ASX-listed shares of ResMed sink after Lilly's drug reduces sleep apnea severity
ASX-listed shares of ResMed slump as much as 6.3% to A$27.050 after Lilly's drug reduces sleep apnea severity. Eli Lilly said its weight-loss drug helped reduce episodes of irregular breathing associated with sleep Apnea. RMD makes devices that are used to treat the sleep-related disorder.
Reuters · 04/18 01:12
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Some good news from a clinical trial conducted by Eli Lilly boosted the pharmaceutical giant's stock. The company published good news on a treatment for obstructive sleep apnea. But the news wasn't taken well by smaller rivals. ResMed and AdaptHealth suffered a 6% and 2% decline, respectively.
The Motley Fool · 04/17 22:51
Wednesday Sector Laggards: Healthcare, Technology & Communications
NASDAQ · 04/17 19:04
ResMed Down Nearly 6%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
ResMed Inc. Is currently at $173.84, down $11.02 or 5.96% -- Would be lowest close since Feb. 29, 2024. Currently down six consecutive days; down 10.51% over this period. Down 41.54% from its all-time closing high of $297.36.
Dow Jones · 04/17 17:46
Notable Wednesday Option Activity: RMD, HES, STLD
NASDAQ · 04/17 17:32
More
Webull provides a variety of real-time RMD stock news. You can receive the latest news about Resmed through multiple platforms. This information may help you make smarter investment decisions.
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company’s segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers.